Compare NATH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATH | ENGN |
|---|---|---|
| Founded | 1916 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.9M | 117.2M |
| IPO Year | 1996 | 2023 |
| Metric | NATH | ENGN |
|---|---|---|
| Price | $98.00 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.08 |
| AVG Volume (30 Days) | 17.0K | ★ 697.3K |
| Earning Date | 06-09-2026 | 06-11-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $104,201,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.78 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.67 | $1.40 |
| 52 Week High | $113.59 | $12.25 |
| Indicator | NATH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 52.82 |
| Support Level | $97.73 | $1.67 |
| Resistance Level | $99.02 | $1.96 |
| Average True Range (ATR) | 0.83 | 0.08 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 71.58 | 57.89 |
Nathan's Famous Inc is a branded licensor, wholesaler and retailer of products marketed under its brand. Its products are currently marketed for sale in thousands of locations, including supermarkets, mass merchandisers and club stores, selected foodservice locations and its company-owned and franchised restaurants throughout the United States and in twenty foreign countries. It considers itself to be in the foodservice industry. It has three segments Branded Product Program, Product Licensing, Restaurant Operations, of which majority of revenue is from Branded Product Program which derives from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors. It generates majority of revenue from United States.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.